Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Ainos’ dual play in low-dose interferon therapeutics and AI Nose diagnostics often means skimming hundreds of dense pages. Clinical trial data, VOC-sensor patents, and licensing details are scattered across 10-K risk factors, 10-Q footnotes, and 8-K partnership updates—information critical to anyone tracking this innovative biotech.
Stock Titan solves that problem. Our AI engine turns every new Ainos quarterly earnings report 10-Q filing into plain-English snapshots minutes after it hits EDGAR. Looking for Ainos insider trading Form 4 transactions or need Ainos Form 4 insider transactions real-time? You’ll get instant alerts and context. Want Ainos annual report 10-K simplified? We highlight R&D spend, FDA milestones, and AI Nose commercial timelines. Each document—whether an 8-K material events explained notice or the proxy statement executive compensation schedule—arrives with side-by-side figures, trend charts, and plain-language explanations.
The result: faster, smarter decisions. Compare spend across clinical programs, monitor Ainos executive stock transactions Form 4 before trial readouts, or dive into Ainos earnings report filing analysis without wading through accounting jargon. Our coverage spans every form: S-1 capital raises, Ainos proxy statement executive compensation disclosures, even niche submissions. With real-time feeds and understanding Ainos SEC documents with AI summaries, you’ll never miss a material update again.
Taiwan Carbon Nano Technology Corporation, identified as a director of Ainos, Inc. (AIMD), reported two open-market stock sales. On 09/30/2025 the reporting person sold 1,006 shares at $3.5167 each, reducing beneficial holdings to 1,047,906 shares. On 10/01/2025 they sold 1,700 shares at $3.4633, reducing holdings to 1,046,206 shares. The filing states the shares were sold for general operating purposes. The transactions are reported as direct beneficial ownership and coded as sales.
Ainos, Inc. provides details in its definitive proxy about ownership, director compensation and executive pay adjustments. Two large shareholders are disclosed: Taiwan Carbon Nano Technology Corporation holds 5,500,000 shares (35.64%) and ASE Test, Inc. holds 2,312,077 shares (13.05%). The document discloses board compensation rates including an annual chair retainer of $14,000, audit chair $7,000, compensation chair $4,500, audit committee members $4,000, and compensation committee members $3,000. Director ages are listed (examples: Wen-Han Chang 62; Yao-Chung Chiang 73; Pao-Sheng Wei 67). Chun-Hsien Tsai served as CEO and received a 2023 base salary of $122,517, bonus $115,313 and stock awards valued at $63,692. The proxy includes adjustments used to calculate "compensation actually paid" and reports total compensation actually paid figures (examples: $209,991, $440,794, $223,625, $551,615). The board will solicit proxies to ratify YCM as the independent registered public accounting firm for fiscal 2024 and to authorize adjournment of the annual meeting.
FAQ
What is the current stock price of Ainos (AIMD)?
What is the market cap of Ainos (AIMD)?
